The sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix has been highlighted in a long-term follow-up study. Women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine were followed for more than nine years, and vaccine efficacy (VE) against incident infection was 100%. This is the longest follow-up report for a licensed HPV vaccine. Visit http://ift.tt/1rYeSyT for ...
Read MoreYou have just read an article categorized health
titled Long-Term Follow-Up Highlights Sustained Efficacy, Immunogenicity, and Safety for GlaxoSmithKline's HPV Vaccine.
Written by:
editor - Saturday, August 2, 2014
There are currently no comments for "Long-Term Follow-Up Highlights Sustained Efficacy, Immunogenicity, and Safety for GlaxoSmithKline's HPV Vaccine"
Post a Comment